US senators are introducing legislation to end pay-off deals that keep generic drugs off shelves and give pharmaceutical giants market exclusivity that costs consumers billions of dollars per year. The bid follows Thursday’s release of a Federal Trade Commission report documenting a significant rise in the number of so-called “pay-for-delay”…
The US Supreme Court has decided to take up a case over whether pharmaceutical companies can pay makers of generic drugs to delay release of out of patent drugs. The case centers on the maker of a hormonal treatment called Androgel by Solvay, which is owned by US drug maker…